{"id":1096,"date":"2020-09-28T00:00:00","date_gmt":"2020-09-28T00:00:00","guid":{"rendered":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/09\/28\/company-pays-60-million-to-settle-pelvic-mesh-case\/"},"modified":"2020-09-29T16:10:06","modified_gmt":"2020-09-29T16:10:06","slug":"company-pays-60-million-to-settle-pelvic-mesh-case","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/09\/28\/company-pays-60-million-to-settle-pelvic-mesh-case\/","title":{"rendered":"Company Pays $60 Million to Settle Pelvic Mesh Case"},"content":{"rendered":"

Payment will be shared by 48 states and the District of Columbia<\/h3>\n

<\/b><\/p>\n

<\/b><\/p>\n

MONDAY, Sept. 28, 2020 (HealthDay News) — A company has agreed to pay $60 million to settle charges by U.S. state attorneys general that it failed to adequately inform women of dangerous side effects associated with permanent pelvic mesh devices.<\/p>\n

The payment by C.R. Bard Inc. and its parent company Becton, Dickinson and Co. will be shared by 48 states and the District of Columbia, CBS News<\/i> reported.<\/p>\n

“Bard failed to disclose serious and life-altering risks of permanently implanted surgical mesh devices, leaving thousands of women to suffer,” Mississippi Attorney General Lynn Fitch said in a statement. “This settlement holds Bard accountable for its deceptive business practices.”<\/p>\n

C.R. Bard and its parent company have denied any allegations of wrongdoing, and chose to settle the matter “to avoid the time and expense of further litigation,” according to Troy Kirkpatrick, a spokesperson for Becton, Dickinson and Co., CBS News<\/i> reported.<\/p>\n

CBS News<\/i> Article<\/a><\/p>\n

<\/i><\/p>\n

Copyright \u00a9 2020 HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"

Payment will be shared by 48 states and the District of Columbia<\/p>\n","protected":false},"author":4,"featured_media":1115,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[85],"tags":[],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/1096"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=1096"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/1096\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media\/1115"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=1096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=1096"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=1096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}